At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
TAS 102 +1 moredrug
Likely dose
Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 27, 2018·Updated Mar 2, 2026
In Brief
A Phase 2 clinical trial evaluating TAS 102 and Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA] for Gastric Adenocarcinoma and 2 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartDec 2018
Primary CompletionJan 2022
Study CompletionMay 2024
TodayJul 2026
First PostedSep 27, 2018
Enrollment StartDec 20, 2018
Primary CompletionJan 19, 2022
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.8 years ago
Interventions
TAS 102drug
TAS 102 35 mg will be administered orally twice daily every 2 weeks.
Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]drug
Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.